Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $835000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 34.77% to $835000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $835000.0, a 34.77% decrease, with the full-year FY2024 number at $1.1 million, up 8.74% from a year prior.
  • Non-Current Deffered Revenue was $835000.0 for Q3 2025 at 4D Molecular Therapeutics, up from $219000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $11.7 million in Q1 2021 to a low of $219000.0 in Q2 2025.
  • A 5-year average of $1.8 million and a median of $1.1 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: crashed 84.94% in 2022, then surged 55.61% in 2024.
  • 4D Molecular Therapeutics' Non-Current Deffered Revenue stood at $2.5 million in 2021, then plummeted by 56.8% to $1.1 million in 2022, then dropped by 9.67% to $972000.0 in 2023, then rose by 8.74% to $1.1 million in 2024, then dropped by 21.0% to $835000.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Non-Current Deffered Revenue are $835000.0 (Q3 2025), $219000.0 (Q2 2025), and $434000.0 (Q1 2025).